Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms

Cynthia Licona, Jean‐Baptiste Delhorme, Gilles Riegel, Vania Vidimar, Ricardo Cerón‐Camacho, Bastien Boff, Aïna Venkatasamy, Catherine Tomasetto, Priscila da Silva Figueiredo Celestino Gomes, Didier Rognan,

Inorganic Chemistry Frontiers · 2019 · 41 citations · 32 references

Concepts

Abstract

Switching from ruthenium to osmium reduces sensitivity towards ABCB1 resistance for cyclometalated anticancer drugs.

References

32